Q1 2024 Earnings Estimate for AnaptysBio, Inc. Issued By Leerink Partnrs (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Leerink Partnrs issued their Q1 2024 EPS estimates for AnaptysBio in a research report issued on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger anticipates that the biotechnology company will post earnings of ($1.41) per share for the quarter. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.25) per share. Leerink Partnrs also issued estimates for AnaptysBio’s Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, FY2024 earnings at ($5.71) EPS, Q1 2025 earnings at ($1.91) EPS, Q2 2025 earnings at ($1.86) EPS, Q3 2025 earnings at ($1.85) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($6.37) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at ($3.95) EPS and FY2028 earnings at ($3.39) EPS.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. The firm had revenue of $9.01 million during the quarter, compared to analysts’ expectations of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%.

Several other research analysts have also recently weighed in on ANAB. SVB Leerink assumed coverage on shares of AnaptysBio in a report on Tuesday. They issued an “outperform” rating and a $47.00 price target for the company. Piper Sandler assumed coverage on shares of AnaptysBio in a report on Friday, February 16th. They issued an “overweight” rating and a $80.00 price target for the company. Wells Fargo & Company assumed coverage on shares of AnaptysBio in a report on Thursday, April 11th. They issued an “overweight” rating and a $56.00 price target for the company. Stifel Nicolaus initiated coverage on shares of AnaptysBio in a report on Wednesday, February 21st. They issued a “buy” rating and a $50.00 price target for the company. Finally, BTIG Research initiated coverage on shares of AnaptysBio in a report on Monday, February 26th. They set a “buy” rating and a $55.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.22.

AnaptysBio Stock Up 0.6 %

AnaptysBio stock opened at $21.47 on Thursday. The stock has a market capitalization of $574.54 million, a PE ratio of -3.53 and a beta of -0.30. AnaptysBio has a twelve month low of $13.36 and a twelve month high of $27.50. The company has a 50 day moving average of $23.38 and a 200-day moving average of $20.55.

Insider Activity

In other news, CEO Daniel Faga sold 145,940 shares of the stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $22.78, for a total value of $3,324,513.20. Following the transaction, the chief executive officer now directly owns 752,087 shares of the company’s stock, valued at $17,132,541.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Dennis Mulroy sold 3,065 shares of the company’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $23.63, for a total value of $72,425.95. Following the transaction, the chief financial officer now directly owns 964 shares in the company, valued at $22,779.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Faga sold 145,940 shares of the company’s stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the completion of the transaction, the chief executive officer now owns 752,087 shares in the company, valued at $17,132,541.86. The disclosure for this sale can be found here. Insiders have sold 157,005 shares of company stock valued at $3,586,199 over the last ninety days. 35.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AnaptysBio

Large investors have recently bought and sold shares of the company. Quantbot Technologies LP acquired a new stake in AnaptysBio during the second quarter worth about $34,000. China Universal Asset Management Co. Ltd. grew its stake in AnaptysBio by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock worth $66,000 after buying an additional 2,390 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in AnaptysBio by 248.8% during the third quarter. Tower Research Capital LLC TRC now owns 3,596 shares of the biotechnology company’s stock worth $65,000 after buying an additional 2,565 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in AnaptysBio by 75.4% during the second quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock worth $101,000 after buying an additional 2,142 shares in the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of AnaptysBio in the 4th quarter valued at approximately $119,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.